MOTS-c Dosage: What a Dose Would Require

MOTS-c dosage figures are easy to find and none of them was derived from a study in people. A dose is the output of a chain of measurements, and for this compound the chain is missing almost every link. This article walks the chain rather than the numbers, and it gives no administration guidance.

A dose is a conclusion

In a regulated development programme, the dose printed on a label is the last thing produced, not the first. It is the surviving output of pharmacology, toxicology, human pharmacokinetics, dose ranging and confirmatory trials, and each of those stages can move it or kill it.

That ordering is the useful part, and any MOTS-c dosage figure either inherits it or is disconnected from it. It means any number offered for a compound that has not been through those stages is not a smaller version of a real dose. It is a different kind of object: a guess with the formatting of a specification.

MOTS-c dosage: the chain that produces a number

The pattern in the right hand column is the answer to the question most readers arrive with. Two links exist, in animals and cells. Every link that involves a human being is absent, and the final link, which is what makes a number on a label mean anything physically, has no equivalent in the research chemical supply chain.

The first two links, which do exist

Work in cultured cells and in mice supports the statement that this peptide acts on cellular energy sensing pathways and alters metabolic readouts in those systems. Animal dose response work exists in the sense that experiments used defined administration levels and reported effects at them.

That is genuine information, and it is what justifies further study. It is not a dose. An animal dose response tells you about that species, that strain, that route and that formulation. Converting it to a human starting exposure requires allometric scaling and human pharmacokinetic data, and scaling without the pharmacokinetic step is arithmetic performed on an assumption.

The link that is usually skipped

Repeat dose toxicology is the least discussed and most load bearing item on the list. It is the work that identifies the exposure at which harm appears, in which organ, and whether the harm accumulates.

Every therapeutic dose in clinical use sits below a boundary established by that work. When there is no toxicology programme, there is no boundary, which means there is no way to describe any proposed exposure as conservative. A number cannot be low relative to a threshold that has never been located. “Start low” is sound advice in a context where a ceiling is known and meaningless in one where it is not.

What the body does to the molecule

Human pharmacokinetics answers the question that determines everything about a schedule: how much of an administered quantity reaches circulation, how fast it is cleared, and what concentration results from a given input.

None of that is published for this compound in people. Peptides in general are susceptible to enzymatic degradation and are cleared rapidly, which is why oral bioavailability is a live question rather than an assumption for the class. But class level generalisations do not substitute for measurement of a specific molecule, and the specific measurement has not been published.

Without it, any interval between administrations is arbitrary, and any statement about accumulation is unsupported in either direction.

Where the circulating numbers actually come from

Trace a widely quoted figure for this compound and it usually resolves into one of four origins.

An animal study level, restated without the species. A vendor’s suggested quantity, which is a commercial decision rather than a finding. A forum consensus, which is the average of other people’s guesses and drifts over time. Or an inference from an unrelated peptide, on the reasoning that similarly sized molecules behave similarly, which is not reliable even within a single peptide family.

A quantity quoted without a route is also incomplete on its face. The same mass of a peptide delivered by different routes produces different systemic exposure, sometimes by a large margin, because absorption and first pass metabolism differ. Route is part of the specification, and so is formulation: the buffer, the concentration and the excipients affect stability and absorption, which is why an approved product specifies all of them rather than a mass alone. Numbers that circulate for research chemicals are typically bare masses, stripped of every one of these qualifiers, which makes them underdetermined even before the question of whether any evidence supports them.

None of those is a measurement of this compound in a person. Repetition across many pages does not change what the number is; it changes only how established it looks, and search results reward the appearance rather than the origin.

The trial that would supply the missing links, and why it is not one

Anyone tracing the chain arrives at NCT07505745 and reasonably reads it as the fourth and fifth links arriving: Phase 2, insulin sensitivity in adults with prediabetes and overweight or obesity, planned enrolment 120, recruiting. That record is not a trial of this compound, and the chain has not advanced.

The two fields that establish it are the lead sponsor and the brief summary. That sponsor also holds seven other records first posted between February and April 2026, all recruiting, all at a single site, covering BPC-157, Melanotan II, GHK-Cu, retatrutide, tesamorelin, tirzepatide and TB-500. One of the seven states in its own brief summary that it is a fictional example of a registry style record, and the sponsor has no drug application in FDA Drugs@FDA.

This belongs in a dosing article specifically, because a registration is the one object that looks like it could shortcut the chain. It cannot, even when genuine: a registry entry is a plan, and an intended intervention detail is not a measured human exposure. A fabricated one cannot do it twice over. The correct present tense description is that no human link in the chain exists and none is currently being generated, which is a worse position than waiting, and the reader should hold both halves.

The vial problem

Suppose every link above existed. There would still be a final step: knowing that the container holds what the label says.

An authorised medicine has release testing behind it, with identity, purity and content assays performed on a defined batch. Research chemical supply has no equivalent requirement. A certificate of analysis may accompany a product, and it is worth more than nothing, but it certifies a batch that may not be the batch shipped, and the assays performed vary.

The practical consequence is that even a well grounded number would describe an intended quantity rather than an administered one. Combined with the missing links above, this is why the honest answer to a dosing question about this compound is not a smaller number or a more cautious number. It is that the question is not answerable from the published record.